Table 3.

Preclinical pharmacokinetics of pascolizumab following chronic monthly dosing for 9 months in cynomolgus monkeys

	Males (n = 3)				Females (n = 3)
	Observed mean Cmax,* µg/ml		Mean AUC(0–4 week), µg h/ml		Observed mean Cmax,* µg/ml		Mean AUC(0–4 week), µg h/ml
Dose group, mg/kg (route)	Dose 1	Dose 5	Dose 1	Dose 5	Dose 1	Dose 5	Dose 1	Dose 5
10 (s.c.)	105	117	30 669	32 043	113	119	30 136	33 382
10 (i.v.)	164	174	38 921	43 178	152	155	40 588	33 850
100 (i.v.)	1351	1771	286 688	384 808	1175	1879	257 995	364 559

C_max = maximal drug concentration; AUC = area under the curve; s.c. = subcutaneous; i.v. = intravenous.

^*C_max values were generally observed at the first sampling time, approximately 24 h post-dosing.